Results 31 to 40 of about 491,626 (323)

Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia

Case Reports in Hematology, 2023
Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome ...
Mako Ikeda, Wataru Nakahara, Mizuki Asako, Yuka Umeki, Yoshiki Matsuoka, Takuya Terakawa, Hitomi Matsunaga, Yuki Iwasa, Riko Saito, Yuki Iwama, Takahiro Matsui, Kazumasa Oka, Shuji Ueda   +12 more
doaj   +1 more source

Blastic transformation of mantle cell lymphoma with B-lymphoblastic features

Human Pathology: Case Reports, 2019
Mantle cell lymphoma is characterized by the presence of the t(11;14)(q13;q32), which is found in more than 95% of cases. We present a case of mantle cell lymphoma with the typical phenotype, which transformed to a blastic morphology with loss of ...
David Cantu, Yuridia Alvarado, Joyce Murata-Collins, Dennis D. Weisenburger   +3 more
doaj   +1 more source

B‐cell lymphoblastic lymphoma of the nictitating membrane as the first presenting sign in a 2‐year‐old Springer Spaniel

Clinical Case Reports, 2018
Key Clinical Message B‐cell lymphoblastic lymphoma is an aggressive malignant disease. Necropsy and microscopical examination revealed widespread disease with a high proliferation index.
Frederik Holm, Tommy Hardon, Erik Clasen‐Linde, Lauge Hjorth Mikkelsen, Steffen Heegaard   +4 more
doaj   +1 more source

How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.

Blood, 2019
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Nevertheless, despite a lack of incorporation of novel agents, the development of intensified T-ALL focused ...
D. Teachey, D. O’Connor
semanticscholar   +1 more source

Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma

Scientific Reports, 2019
Fusions transcripts have been proven to be strong drivers for neoplasia-associated mutations, although their incidence in T-cell lymphoblastic lymphoma needs to be determined yet.
P. López-Nieva, P. Fernández-Navarro, Osvaldo Graña-Castro, Eduardo Andrés-León, Javier Santos, M. Villa-Morales, M. A. Cobos-Fernández, Laura González-Sánchez, Marcos Malumbres, María Salazar-Roa, J. Fernández-Piqueras   +10 more
semanticscholar   +1 more source

Transformation of acute lymphoblastic leukemia with a precursor B-cell immunophenotype to burkitt’s lymphoma: A case report [PDF]

Caspian Journal of Internal Medicine, 2023
Background: As a new point, some very rare features can be revealed as initial diagnosis of acute lymphoblastic leukemia (ALL) without any evidence of lymphoma-like behavior which after initial recovery, presents with new evidence of lymphoma.
Masoumeh Jafari, Shahla Ansari Damavandi, Forugh Charmduzi   +2 more
doaj  

Multifocal precursor B-cell lymphoblastic lymphoma in an infant with cardiac involvement: A case report

Radiology Case Reports, 2021
Lymphoma with cardiac involvement is a high-risk lesion, especially in children. We report a rare clinical case of multifocal precursor B-cell lymphoblastic lymphoma in a child with cardiac involvement.
Tran Phan Ninh, MD, PhD, Nguyen Minh Duc, MD, Nguyen Ngoc Trung, MD, PhD, Le Anh Duc, MD, PhD, Doan-Van Ngoc, MD, PhD, Thieu-Thi Tra My, MD, Nguyen-Van Sang, MD, PhD, Pham Minh Thong, MD, PhD   +7 more
doaj   +1 more source

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Cytometry. Part B, Clinical cytometry, 2020
Flow‐cytometric minimal residual disease (FC‐MRD) monitoring is a well‐established risk‐stratification factor in B‐lymphoblastic leukemia/lymphoma (‐B‐ALL) and is being considered as a basis for deintensification or escalation in treatment protocols ...
P. Tembhare, Papagudi G Subramanian Pg, S. Ghogale, G. Chatterjee, N. Patkar, Avinash Gupta, Rahul Shukla, Y. Badrinath, N. Deshpande, G. Narula, Pearl Rodrigues, K. Girase, D. Dhaliwal, M. Prasad, D. Shetty, S. Banavali, S. Gujral   +16 more
semanticscholar   +1 more source

Risk Factors Influencing Survival in T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia. [PDF]

Cancer Med
Survival outcomes in T‐LBL vs. T‐ALL: Implications for early allogeneic stem cell transplantation. ABSTRACT Background T‐cell lymphoblastic lymphoma (T‐LBL) is a rare non‐Hodgkin lymphoma. The World Health Organization defines T‐LBL and T‐cell acute lymphoblastic leukemia (T‐ALL) as the same entity.
Kim TY, Min KI, Min GJ, Eom KS, Lee S, Cho SG, Kim S, Lee JH, Kim BS, Jeoung JW, Won HS, Yoon JH, Jeon Y.   +12 more
europepmc   +2 more sources

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

Carcinogenesis, 2019
T-cell lymphoblastic lymphoma is a haematological disease with an urgent need for reliable prognostic biomarkers that allow therapeutic stratification and dose adjustment. The scarcity of human samples is responsible for the delayed progress in the study
J. L. Marín-Rubio, E. Pérez-Gómez, J. Fernández-Piqueras, M. Villa-Morales   +3 more
semanticscholar   +1 more source